Regulators Signal Clear Path: Gene Therapies Advance to CommercializationGlobal Report·Aug 25 at 10:12 AMEDIT-3.16%NTLA-1.09%
Asana’s USD 12,000 AI Experiment and the Messy Reality of Tech Infrastructure in 2026Global Report·Aug 20 at 10:16 AMASAN+0.69%EDU-1.92%
The Biotech Boom's Hidden Catch: Progress and Peril in 2026Global Report·Aug 20 at 09:43 AMEDIT-3.16%KYMR+0.56%
Biotech Startups Shift Focus to Near-Term Milestones to Conserve CapitalGlobal Report·Aug 20 at 09:41 AMEDIT-3.16%KYMR+0.56%
CRISPR Comes of Age, But Wall Street Isn't Buying the RevolutionGlobal Report·Aug 11 at 10:11 AMEDIT-3.16%NTLA-1.09%
Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statementPUBT·Aug 7 at 09:16 PMEDIT-3.16%
Editas Medicine names Patrick Ellinor to board, Elliott Levy to step downPUBT·Aug 4 at 09:00 PMEDIT-3.16%
Editas Medicine (NASDAQ:EDIT) EVP Linda Burkly Sells 4,928 Shares of StockMarket Beat·Jul 29 at 09:22 PMEDIT-3.16%
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next?Market Beat·Jul 17 at 07:40 AMEDIT-3.16%
The Biotech Survival Curve: How Milestone Checks and In-Vivo CRISPR Are Rewriting the RulesGlobal Report·Jul 4 at 09:01 AMPRTA+0.21%EDIT-3.16%
